Difference between revisions of "Fludarabine (Fludara)"
| Line 11: | Line 11: | ||
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| + | *[[Mantle cell lymphoma]] | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
Revision as of 15:44, 7 October 2013
General information
Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Aggressive Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Patient drug information
- Fludarabine (Fludara) patient drug information (Chemocare)[3]
- Fludarabine (Fludara) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 4/18/1991: Initial FDA approval
Also known as
Beneflur, FAMP, Fludarabine Phosphate, Fludara Lyophilisat, Oforta, Trav Fludarabine.